newsfilter
← Latest News
GlobeNewswire·

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody